Dr Chris Hand, Chairman of Scientific & Medical Advisory Board
Dr Chris Hand has over 20 years’ experience in the medical diagnostics industry in the development and commercialisation of in vitro diagnostic products. Chris co-founded the medical diagnostics company Cozart Bioscience Ltd and was Chief Executive of Cozart plc, following IPO on AIM in 2004, until October 2007 when the company was sold to Concateno plc for £65 million. Chris was a non-executive director of Concateno plc until its sale to US listed Alere Inc for £147m in August 2009 and stayed with the company as consultant until June 2010. Prior to founding Cozart, Chris was Director of Research for the European base of DPC (now part of Siemens Healthcare Solutions) developing a wide range of immunodiagnostic kits in a variety of formats.
Chris was a non-executive director of Advanced Computer Software plc, the AIM-listed leading software and IT services provider until the sale to Vista Private Equity for £750m in March 2015.
He has a BSc in Applied Biochemistry from Brunel University and a DPhil from the Faculty of Medicine, University of Oxford.
Professor Donal D.C. Bradley CBE, FRS, CEng, FIET, FInstP, FRSA
Professor Donal Bradley is Head of the Mathematical, Physical and Life Sciences (MPLS) Division and Professor of Engineering Science and Physics at the University of Oxford.
Previously Professor Bradley was Vice-Provost (Research), Director of the Centre for Plastic Electronics, and Lee-Lucas Professor of Experimental Physics at Imperial College London. As VP(R) he championed a wide range of cross-faculty research initiatives, including a coordinated translation and impact acceleration programme, and led the successful launch of a pan-College PhD scholarships programme. He also provided pump-priming funding for a variety of new programmes in, for example, Data Science and Engineering, Medical Diagnostics and Advanced Functional Materials, and he oversaw the formation of 12 Imperial-led EPSRC Centres for Doctoral Training.
Professor Bradley’s personal research interests focus on plastic electronics – encompassing fundamental studies on low-temperature/solution processed semiconductor materials and their application in a range of fields including energy efficient displays, lighting and solar panels; sensing and imaging devices; and photonic components for communications. He is a co-inventor of conjugated polymer electroluminescence and a co-founder of Cambridge Display Technology Ltd and Molecular Vision Ltd. He is also a Director of Solar Press (UK) Ltd. Professor Bradley has more than 25 patent families to his name, and is ranked in the top 1% of most highly cited materials science researchers in the world. His research has been recognised by numerous awards and prizes including the IET and IOP Faraday Medals, the Royal Society Bakerian Lecture and the EU Descartes Prize. He was appointed a CBE in 2010 for services to science.
Professor Mark Drayson, MBChB, PhD FRCPath
Professor Mark Drayson is Professor of Clinical Immunodiagnostics, College of Medical and Dental Sciences, University of Birmingham. Director of the Clinical Immunology Service (CIS), Birmingham. He is an Honorary Consultant at University Hospitals Birmingham and Heart of England.
Professor Drayson has directed the CIS since 2000. The service provides a unique interface between the University’s substantial scientific expertise in immunology and the clinical investigation and management of blood cancers, immunodeficiency and autoimmunity in the West Midlands. Providing 500,000 immunodiagnostic tests per year for a population of five million, the CIS is in an ideal position for research and development. He provides central laboratory analysis for UK clinical trials in myeloma and is chief investigator for two. The results of these trials are helping formulate world opinion on investigation and management of the disease. He has played a key role developing and demonstrating the utility of tests for serum immunoglobulin free light chains in myeloma, other B-cell dyscrasias and related conditions.
Professor Drayson has developed a second generation of the test (‘Seralite®‘) which is a rapid test based on monoclonal antibodies. This is being commercialised by Abingdon Health Ltd, providing improved laboratory and unique near-patient versions of the test. He is a member of national and international guidelines groups for diagnosis and management of myeloma and MGUS (Monoclonal Gammopathy of Unknown Significance). His basic research in blood cancers is finding new therapies for blood cancers by drug redeployment which he is testing in trials in the UK and Africa. He has major grants from Cancer Research UK, Leukaemia Lymphoma Research, Medical Research Council and National Institute of Health Research.
© Abingdon Health 2018